Literature DB >> 20228232

A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.

Steven N Hart1, Ye Li, Kaori Nakamoto, Eva-anne Subileau, David Steen, Xiao-bo Zhong.   

Abstract

HepaRG cells, derived from a female hepatocarcinoma patient, are capable of differentiating into biliary epithelial cells and hepatocytes. More importantly, differentiated HepaRG cells are able to maintain activities of many xenobiotic-metabolizing enzymes, and expression of the metabolizing enzyme genes can be induced by xenobiotics. The ability of these cells to express and induce xenobiotic-metabolizing enzymes is in stark contrast to the frequently used HepG2 cells. The previous studies have mainly focused on a set of selected genes; therefore, it is of significant interest to know the extent of similarity of gene expression at whole genome levels in HepaRG cells and HepG2 cells compared with primary human hepatocytes and human liver tissues. To accomplish this objective, we used Affymetrix (Santa Clara, CA) U133 Plus 2.0 arrays to characterize the whole genome gene expression profiles in triplicate biological samples from HepG2 cells, HepaRG cells (undifferentiated and differentiated cells), freshly isolated primary human hepatocytes, and frozen liver tissues. After using similarity matrix, principal components, and hierarchical clustering methods, we found that HepaRG cells globally transcribe genes at levels more similar to human primary hepatocytes and human liver tissues than HepG2 cells. In particular, many genes encoding drug-processing proteins are transcribed at a more similar level in HepaRG cells than in HepG2 cells compared with primary human hepatocytes and liver samples. The transcriptomic similarity of HepaRG with primary human hepatocytes is encouraging for use of HepaRG cells in the study of xenobiotic metabolism, hepatotoxicology, and hepatocyte differentiation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20228232      PMCID: PMC2879958          DOI: 10.1124/dmd.109.031831

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  22 in total

1.  Timing of new black box warnings and withdrawals for prescription medications.

Authors:  Karen E Lasser; Paul D Allen; Steffie J Woolhandler; David U Himmelstein; Sidney M Wolfe; David H Bor
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

Review 2.  Concordance of the toxicity of pharmaceuticals in humans and in animals.

Authors:  H Olson; G Betton; D Robinson; K Thomas; A Monro; G Kolaja; P Lilly; J Sanders; G Sipes; W Bracken; M Dorato; K Van Deun; P Smith; B Berger; A Heller
Journal:  Regul Toxicol Pharmacol       Date:  2000-08       Impact factor: 3.271

Review 3.  Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies.

Authors:  Nicola J Hewitt; María José Gómez Lechón; J Brian Houston; David Hallifax; Hayley S Brown; Patrick Maurel; J Gerald Kenna; Lena Gustavsson; Christina Lohmann; Christian Skonberg; Andre Guillouzo; Gregor Tuschl; Albert P Li; Edward LeCluyse; Geny M M Groothuis; Jan G Hengstler
Journal:  Drug Metab Rev       Date:  2007       Impact factor: 4.518

4.  Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line.

Authors:  Marc Le Vee; Emilie Jigorel; Denise Glaise; Philippe Gripon; Christiane Guguen-Guillouzo; Olivier Fardel
Journal:  Eur J Pharm Sci       Date:  2006-02-20       Impact factor: 4.384

5.  Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions.

Authors:  Carine B Lambert; Catherine Spire; Marie-Pierre Renaud; Nancy Claude; Andre Guillouzo
Journal:  Toxicol In Vitro       Date:  2008-12-30       Impact factor: 3.500

6.  Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells.

Authors:  Caroline Aninat; Amélie Piton; Denise Glaise; Typhen Le Charpentier; Sophie Langouët; Fabrice Morel; Christiane Guguen-Guillouzo; André Guillouzo
Journal:  Drug Metab Dispos       Date:  2005-10-04       Impact factor: 3.922

7.  Drug metabolism by the human hepatoma cell, Hep G2.

Authors:  S Sassa; O Sugita; R A Galbraith; A Kappas
Journal:  Biochem Biophys Res Commun       Date:  1987-02-27       Impact factor: 3.575

Review 8.  Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation.

Authors:  E L LeCluyse
Journal:  Eur J Pharm Sci       Date:  2001-07       Impact factor: 4.384

Review 9.  The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.

Authors:  André Guillouzo; Anne Corlu; Caroline Aninat; Denise Glaise; Fabrice Morel; Christiane Guguen-Guillouzo
Journal:  Chem Biol Interact       Date:  2006-12-16       Impact factor: 5.192

10.  Gene expression in human hepatocytes in suspension after isolation is similar to the liver of origin, is not affected by hepatocyte cold storage and cryopreservation, but is strongly changed after hepatocyte plating.

Authors:  Lysiane Richert; Michael J Liguori; Catherine Abadie; Bruno Heyd; Georges Mantion; Nermin Halkic; Jeffrey F Waring
Journal:  Drug Metab Dispos       Date:  2006-02-10       Impact factor: 3.922

View more
  77 in total

1.  Genome-wide analysis of human constitutive androstane receptor (CAR) transcriptome in wild-type and CAR-knockout HepaRG cells.

Authors:  Daochuan Li; Bryan Mackowiak; Timothy G Brayman; Michael Mitchell; Lei Zhang; Shiew-Mei Huang; Hongbing Wang
Journal:  Biochem Pharmacol       Date:  2015-08-12       Impact factor: 5.858

2.  Regulation of Cytosolic Sulfotransferases in Models of Human Hepatocyte Development.

Authors:  Sarah Dubaisi; Kathleen G Barrett; Hailin Fang; Jorge Guzman-Lepe; Alejandro Soto-Gutierrez; Thomas A Kocarek; Melissa Runge-Morris
Journal:  Drug Metab Dispos       Date:  2018-06-01       Impact factor: 3.922

3.  Evaluation of the HC-04 cell line as an in vitro model for mechanistic assessment of changes in hepatic cytochrome P450 3A during adenovirus infection.

Authors:  Piyanuch Wonganan; Kristina Jonsson-Schmunk; Shellie M Callahan; Jin Huk Choi; Maria A Croyle
Journal:  Drug Metab Dispos       Date:  2014-04-24       Impact factor: 3.922

4.  Transcriptional and epigenetic landscape of Ca2+-signaling genes in hepatocellular carcinoma.

Authors:  Andrés Hernández-Oliveras; Eduardo Izquierdo-Torres; Guadalupe Hernández-Martínez; Ángel Zarain-Herzberg; Juan Santiago-García
Journal:  J Cell Commun Signal       Date:  2021-01-04       Impact factor: 5.782

5.  Noncoding RNAs as therapeutics for acetaminophen-induced liver injury.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  Stem Cell Investig       Date:  2016-10-11

6.  Genistein, resveratrol, and 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside induce cytochrome P450 4F2 expression through an AMP-activated protein kinase-dependent pathway.

Authors:  Mei-Hui Hsu; Uzen Savas; Jerome M Lasker; Eric F Johnson
Journal:  J Pharmacol Exp Ther       Date:  2011-01-04       Impact factor: 4.030

Review 7.  Emerging In Vitro Liver Technologies for Drug Metabolism and Inter-Organ Interactions.

Authors:  Shyam Sundhar Bale; Laura Moore; Martin Yarmush; Rohit Jindal
Journal:  Tissue Eng Part B Rev       Date:  2016-06-01       Impact factor: 6.389

Review 8.  Liver and Kidney on Chips: Microphysiological Models to Understand Transporter Function.

Authors:  S Y Chang; E J Weber; Kp Van Ness; D L Eaton; E J Kelly
Journal:  Clin Pharmacol Ther       Date:  2016-08-27       Impact factor: 6.875

9.  Increased IGFBP-1 phosphorylation in response to leucine deprivation is mediated by CK2 and PKC.

Authors:  Niyati Malkani; Kyle Biggar; Majida Abu Shehab; Shawn Shun-Cheng Li; Thomas Jansson; Madhulika B Gupta
Journal:  Mol Cell Endocrinol       Date:  2015-12-28       Impact factor: 4.102

10.  3,3'-Dichlorobiphenyl Is Metabolized to a Complex Mixture of Oxidative Metabolites, Including Novel Methoxylated Metabolites, by HepG2 Cells.

Authors:  Chun-Yun Zhang; Susanne Flor; Patricia Ruiz; Ram Dhakal; Xin Hu; Lynn M Teesch; Gabriele Ludewig; Hans-Joachim Lehmler
Journal:  Environ Sci Technol       Date:  2020-09-23       Impact factor: 9.028

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.